Connection

Marco Massari to Antiviral Agents

Back to Details
This is a "connection" page, showing publications Marco Massari has written about Antiviral Agents.
Marco Massari
Connection Strength
0.112
Antiviral Agents
  1. Abdominal Visceral Infarction in 3 Patients with COVID-19. Emerg Infect Dis. 2020 Aug; 26(8):1926-1928.
    View in: PubMed
    Score: 0.020
  2. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 06 11; 382(24):2327-2336.
    View in: PubMed
    Score: 0.020
  3. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017 12; 66(6):1814-1825.
    View in: PubMed
    Score: 0.017
  4. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017; 12(10):e0185728.
    View in: PubMed
    Score: 0.017
  5. What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group. Infez Med. 2017 Jun 01; 25(2):150-157.
    View in: PubMed
    Score: 0.017
  6. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One. 2017; 12(2):e0172159.
    View in: PubMed
    Score: 0.016
  7. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int. 2018 12; 38(12):2190-2198.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.